483
Bristol-Myers Squibb CompanyBristol-Myers Squibb Company – FDA 483, Dec 6, 2024
Record Details
Bristol-Myers Squibb Company, located in Madison, NJ, received a Form 483 for deficiencies in its Risk Evaluation and Mitigation Strategy (REMS) for THALOMID. The inspection revealed failures in adhering to the REMS audit schedule, monitoring patient pregnancy tests, and providing complete training materials to healthcare providers and pharmacies. These issues indicate a lack of robust controls in ensuring the safe use and distribution of the drug.
View Company Profile
ID · 97218ac0-74e3-4a85-83a2-081a9e0504fb
Other documents for Bristol-Myers Squibb Company
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.